Physician profile
Helena Marie Kuhn
NPI 1184061947
$63,330.05
in general payments reported to CMS, 2019-2025
33 companies · $32K in 2025
The $32K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2022: $549 · 2023: $9,276 · 2024: $21K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Consulting Fee: $14K · Food and Beverage: $10K · Travel and Lodging: $1,536 · Education: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,390.00 |
| Consulting Fee | $13,621.00 |
| Food and Beverage | $10,391.98 |
| Travel and Lodging | $1,536.42 |
| Education | $478.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $43,849.18 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $9,698.25 | 2023-2025 | Sotyktu |
| Abbvie INC. | $1,515.83 | 2022-2025 | |
| Janssen Biotech, INC. | $894.57 | 2022-2025 | Tremfya, Simponi, Remicade |
| Incyte Corporation | $866.66 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $834.14 | 2024-2025 | Adbry, Anzupgo |
| Amgen INC. | $818.79 | 2022-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $772.84 | 2019-2025 | Nemluvio, Aklief |
| Arcutis Biotherapeutics, INC. | $528.87 | 2023-2025 | Zoryve |
| Genzyme Corporation | $503.24 | 2023-2025 | |
| Lilly USA, LLC | $475.12 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $419.58 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $388.94 | 2022-2025 | Ilumya |
| Ucb, INC. | $353.05 | 2022-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $232.44 | 2022-2025 | Dupixent, Libtayo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $230.54 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Organon LLC | $147.28 | 2024-2025 | Hadlima, Vtama |
| Allergan, INC. | $97.33 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $96.91 | 2019-2024 | Jublia |
| Sanofi-Aventis U.S. LLC | $94.99 | 2024 | |
| Revance Therapeutics, INC. | $91.05 | 2024 | Daxxify |
| Dermavant Sciences, INC. | $86.50 | 2023 | Vtama |
| Botanix Sb INC | $74.20 | 2025 | Sofdra |
| Krystal Biotech INC | $46.59 | 2023 | Vyjuvek |
| Kyowa Kirin, INC. | $40.29 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $31.53 | 2023 | Seglentis |
| Sandoz INC. | $25.40 | 2024 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.89 | 2025 | Spevigo |
| Solta Medical, A Division of Bausch Health US, LLC | $21.93 | 2025 | Clear & Brilliant |
| Lnhc, INC | $19.06 | 2025 | Zelsuvmi |
| Tactile Systems Technology INC | $17.68 | 2023 | Flexitouch Plus, Entre Plus |
| Janssen Scientific Affairs, LLC | $16.50 | 2022 | |
| Genentech USA, INC. | $15.88 | 2024 | Erivedge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helena Kuhn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.